×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Mechanism: Tau Aggregate Specificity in Progressive Supranuclear Palsy
mechanism
2,028 words
KG: ent-dise-bfd8f32d
2026-04-01
kind:mechanism
section:mechanisms
state:published
Contents
Tau Aggregate Specificity in Progressive Supranuclear Palsy
⚙
Mechanism Info
Name
Tau Aggregate Specificity in Progressive Supranuclear Palsy
Summary
Page for Tau Aggregate Specificity in Progressive Supranuclear Palsy
Knowledge Graph
Related Hypotheses (28)
Adenosine-Astrocyte Metabolic Reset
Score: 0.56
Phase-Separated Organelle Targeting
Score: 0.52
GFAP-Positive Reactive Astrocyte Subtype Delineation
Score: 0.52
Heat Shock Protein 70 Disaggregase Amplification
Score: 0.51
Aquaporin-4 Polarization Rescue
Score: 0.51
Perforant Path Presynaptic Terminal Protection Strategy
Score: 0.48
Chaperone-Mediated APOE4 Refolding Enhancement
Score: 0.48
Metabolic Switch Targeting for A1→A2 Repolarization
Score: 0.48
Tau-Independent Microtubule Stabilization via MAP6 Enhanceme
Score: 0.48
Complement C1q Mimetic Decoy Therapy
Score: 0.48
Metabolic Circuit Breaker via Lipid Droplet Modulation
Score: 0.48
TET2-Mediated Demethylation Rejuvenation Therapy
Score: 0.47
Reelin-Mediated Cytoskeletal Stabilization Protocol
Score: 0.45
HCN1-Mediated Resonance Frequency Stabilization Therapy
Score: 0.44
HSP90-Tau Disaggregation Complex Enhancement
Score: 0.44
Osmotic Gradient Restoration via Selective AQP1 Enhancement
Score: 0.43
R-Loop Resolution Enhancement Therapy
Score: 0.43
Serine/Arginine-Rich Protein Kinase Modulation
Score: 0.42
Biorhythmic Interference via Controlled Sleep Oscillations
Score: 0.41
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.41
Ephrin-B2/EphB4 Axis Manipulation
Score: 0.40
KDM6A-Mediated H3K27me3 Rejuvenation
Score: 0.38
Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancem
Score: 0.38
Designer TRAK1-KIF5 fusion proteins accelerate therapeutic m
Score: 0.35
Trans-Synaptic Adhesion Molecule Modulation
Score: 0.34
Netrin-1 Gradient Restoration
Score: 0.33
Astrocyte-Mediated Neuronal Epigenetic Rescue
Score: 0.48
TREM2-Mediated Selective Aggregate Clearance Pathway
Score: 0.43
Show 23 more
Related Analyses (30)
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Do tau strains or regional cellular environments primarily d
neurodegeneration · failed
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · completed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Mitochondrial transfer between neurons and glia
neurodegeneration · archived
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · archived
Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · archived
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · archived
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Show 25 more
Related Experiments (22)
s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40
Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40
Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40
FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40
Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40
Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40
PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40
Sleep and Respiratory Network Interaction in ALS — Experimen
clinical · proposed · Score: 0.40
TDP-43 PET Ligand Development for FTD and ALS
clinical · proposed · Score: 0.40
Viral and Post-Infectious Mechanisms in ALS — Experiment Des
clinical · proposed · Score: 0.40
Show 17 more